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Background: The Methyl CpG binding protein 2 gene (MeCP2 gene) encodes a critical transcriptional repressor and is
widely expressed in mammalian neurons. MeCP2 plays a critical role in neuronal differentiation, neural development,
and synaptic plasticity. Mutations and duplications of the human MECP2 gene lead to severe neurodevelopmental
disorders, such as Rett syndrome and autism. In this study we investigate the role of MeCP2 in the spinal cord and
found that MeCP2 plays an important role as an analgesic mediator in pain circuitry.
Findings: Experiments using MeCP2 transgenic mice showed that overexpression of MeCP2 weakens both acute
mechanical pain and thermal pain, suggesting an analgesic role of MeCP2 in acute pain transduction. We found that
through p-CREB/miR-132 signaling cascade is involved in MeCP2-mediated pain transduction. We also examined the
role of MeCP2 in chronic pain formation using spared nerve injury (SNI) model. Strikingly, we found that development
of neuropathic pain attenuates in MeCP2 transgenic mice comparing to wild type (WT) mice.
Conclusions: Our study shows that MeCP2 plays an analgesic role in both acute pain transduction and chronic pain
formation through regulating CREB-miR-132 pathway. This work provides a potential therapeutic target for neural
pathologic pain, and also sheds new lights on the abnormal sensory mechanisms associated with autism
spectrum orders.
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Background
Mutations of methyl-CpG binding protein 2 (MeCP2)
lead to Rett syndrome, a severe neurodevelopmental dis-
order [1]. Whereas, duplications of mecp2 locus lead to
severe autism spectrum disorders in human patients [2].
Dysfunctions of pain sensitivity have been reported in
human Rett syndrome patients [3]. Interestingly, it is re-
cently reported that MeCP2 plays a critical role in per-
sistent pain sensation through central mechanisms [4].
To mimic MECP2 duplication syndrome, genomic seg-
ment containing human MECP2 gene has been intro-
duced into the mouse genome [5]. Mice carrying human
MECP2 transgene appear to have defects in social inter-
action, anxiety, and motor functions [6]. Whether pain* Correspondence: zqiu@ion.ac.cn; liyang.chiang@gmail.com
2Institute of Neuroscience, Key Laboratory for Primate Neurobiology, Chinese
Academy of Sciences, Shanghai, China
1The Key Laboratory of Developmental Genes and Human Disease, Ministry
of Education, Institute of Life Sciences, Southeast University, Nanjing, China
Full list of author information is available at the end of the article
© 2015 Zhang et al.; licensee BioMed Central.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.sensation would be altered in mecp2 transgenic mice or
human patients with MECP2 duplication syndrome
are unknown.
Peripheral nerve injury causes not only central
sensitization [7], but also protection mechanism against
injury. Central sensitization represents for an enhance-
ment in the function of neurons and formation of cir-
cuits in nociceptive pathways caused by increases in
membrane excitability and synaptic efficacy as well as re-
duced inhibition and a manifestation of the remarkable
plasticity of the somatosensory nervous system in re-
sponse to activity, inflammation, and neural injury [8].
Protection responses include remodeling of nervous sys-
tem circuitry related to the lost functions [9] and intrin-
sic mechanisms of pain inhibition [10,11]. Under the
condition of neuropathic pain, a wide range of functional
genes need to be expressed [12,13] when protection
response occurs.
MeCP2 expresses predominantly in mature neurons
[14]. It acts as transcriptional repressor factor through
its methyl CpG binding domain and transcriptionalThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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MeCP2 can also activate gene expression of a variety of
genes such as brain-derived neurotrophic factor (BDNF)
[17,18]. In recent studies, microRNAs attract more and
more attention in post-transcriptional regulation of gene
expression. MicroRNAs are short RNA transcripts with
20 ~ 25 bp that regulate gene expression through com-
plementary pairing with 3′UTR of mRNAs thus prevent
translation [19]. Studies showed that miR-132 can be in-
duced by p-CREB [20]and take part in restricting MeCP2
level within a narrow range [21,22].
Previous study suggests that 75.2% of Rett Syndrome
patients induced by MeCP2 mutation have a deficit in
normal pain response [3]. In rat experiments, researchers
using microarray analysis found that most genes that are
regulated in inflammatory pain are either MeCP2 target
genes or genes that can form transcriptional repressor
compound with MeCP2 [23]. In both neuropathic pain
and inflammatory pain models, it is found that MeCP2 ex-
pression or p-MeCP2 has a significant change [24,25]. All
of these suggest a relationship between MeCP2 and pain
sensitivity.
Our results show that MeCP2 overexpression attenu-
ates both mechanical and thermal pain sensitivity. The
mechanism is through CREB/miR-132 signaling pathway
in spinal cord. This suggests a novel therapeutic ap-
proach for suppressing formation of chronic pain using
MeCP2 as a target gene.
Results
The role of MeCP2 in acute pain sensitivity
We used wild-type (WT) and transgenic mice overex-
pressing MeCP2 (OE) to examine whether MeCP2 is in-
volved in pain sensitivity. Both mechanical sensitivity
and thermal sensitivity were investigated by various
tests. Paw withdrawal threshold was studied using the
von Frey test. We found that MeCP2 OE mice had a sig-
nificantly higher paw withdrawal threshold than WT
mice (Figure 1A). Under thermal stimulation, MeCP2
OE mice showed significantly longer latency in tail
immersion than WT at both 48°C and 52°C (Figure 1B).
These results suggest that MeCP2 plays a critical role in
pain sensitivity modulation.
MeCP2 weakens pain sensitivity through central mechanism
MeCP2 expression level changes under pain condition
[24,25], but the mechanism of its involvement in pain
states remains unknown. Previous studies identified the
ischemic stimulus that triggers an endogenous, neuro-
protective response which protects the brain during a
subsequent severe ischemic injury through a rapid in-
crease in MeCP2 protein [22]. So the location of MeCP2
and how it changes under pain conditions should
be investigated.In our experiments, frozen sections of DRG and spinal
cord were obtained from lumbar L4-L6. Co-localization
of MeCP2 with nociceptive neurons and non nociceptive
neurons were investigated using immunofluorescence,
which demonstrated that all pain sensitive neurons (IB4
and TRPV1 positive) as well as non nociceptive neurons
(NF200 positive) displayed MeCP2 expression. This find-
ing provided the material proof for MeCP2 taking part
in pain states (Figure 2A).
The Spared nerve injury (SNI) model was used to
study MeCP2 expression under pain conditions. We per-
formed a time series of 10 days and 13 days to observe
variation tendency of MeCP2 in Dorsal root ganglion
(DRG) and spinal cord respectively. In DRG, MeCP2
protein level was down-regulated after SNI (Figure 2B
and C). In spinal cord, MeCP2 protein level was ele-
vated from 3d to 7d after SNI, and then down-regulated
(Figure 2D and E). So MeCP2 may act as a protective
factor in central system under neuropathic pain.
The role of MeCP2 in chronic pain
Despite considerable knowledge of the pain mechanism
having been accumulated [12,13,26], there is no consum-
mate treatment for chronic pain. Since MeCP2 is critical
for pain sensitivity (Figure 1) and its upregulation for
protective responses under pain condition (Figure 2D
and E), there would be a new research direction if ele-
vating MeCP2 may suppress the sense of pain.
We next further examine the role of MeCP2 in
chronic pain using WT and MeCP2 OE mice. The right
hindpaws of WT mice were regarded as control. The left
hindpaws of WT mice and MeCP2 overexpression mice
were followed by SNI. In von Frey test, hindpaws after
SNI showed significant reduction in withdrawal thresh-
old compared to contralateral hindpaws, while MeCP2
OE mice only shows a slight downgrade in paw with-
drawal threshold and their withdrawal threshold after
SNI had no difference compared with WT contralateral
(Figure 3). These evidence strongly suggests that MeCP2
could suppress sense of pain.
CREB/miR-132 pathway is involved in the protective
response of MeCP2
MeCP2 is generally a transcriptional repressor factor
[16]. Its upregulation leads to suppression of target
genes [15]. MeCP2 is also the target of others regulators
[21]. Both MeCP2 mutation and overexpression will lead
to neurological diseases, which suggest that MeCP2 ex-
pression in the proper range is necessary for normal
physiological function. We found that mRNA level of
MeCP2 did not change significantly after SNI, but the
protein level was elevated (Figure 4A). So change of
MeCP2 expression was at the post-transcriptional level.
MicroRNAs are short RNA transcripts with 20 ~ 25 bp
Figure 1 MeCP2 overexpression attenuates both mechanical and thermal pain sensitivity. A, Comparison of paw withdrawal threshold to
mechanical stimulation between WT mice and MeCP2 overexpression mice (OE). 7 mice were tested in each group. B, Comparison of pain
sensitivity to thermal stimulation between WT mice and MeCP2 overexpression mice (OE). n = 9 for WT and OE respectively. All values are
represented as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
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level. Several studies have found that MeCP2 can be reg-
ulated by miRNAs especially miR-132 in specific areas of
the brain. Spinal cord may share the similar mechanism
with brain. Thus we would like to examine levels of
miR-132 in SNI experiments. We found that expres-
sion of miR-132 were detected in Spinal cord after SNI
(Figure 4B). Interestingly, miR-132 was downregulated
by 3d to 7d after SNI (Figure 4B).
The induction and persistent stages of pain is a bal-
anced process between pain-induction and self-repair in
which new proteins needed to be synthesis. Some are
“pain genes” like c-fos, a product of immediate earlyFigure 2 MeCP2 weakens pain sensitivity through central mechanism. A, T
(DH). In DRG, all IB4 (red) positive neurons and NF200 (blue) positive neurons h
neurons have MeCP2 (green) expression (mid panel). In DH, MeCP2 expressed
pictures show single focal plane. Scale bars, 50 μm. B, In DRG, MeCP2 protein l
expression in DRG. D, In spinal cord, MeCP2 protein level was elevated by 3d t
MeCP2 expression in spinal cord. Bars are relative protein level to control withogene that is induced by p-CREB [27,28]. Others are
“Analgesic genes”. In the induction period of neuro-
pathic pain, the phosphorylation level of cAMP re-
sponse element binding protein (p-CREB S133) was
elevated rapidly to activate pain-related genes (Figure 4C
and D). C-fos is one of the target genes that is induced
by p-CREB. From 3 days to 7 days after SNI, the p-
CREB level returned (Figure 4C and D). miR-132 that is
induced by p-CREB was also downregulated (Figure 4B).
miR-132 forms complementary pairing with 3′UTR of
MeCP2 and prevent its expression at post-transcriptional
level. MeCP2 was released to express when miR-132 de-
crease and provided injury body a protective response.he location of MeCP2 expression in DRG and spinal cord dorsal horn
ave MeCP2 (green) expression (upper panel). All TRPV1 (blue) positive
more intense than other area of spinal cord (lower panel). Representative
evel was downregulated after SNI. C, Relative protein levels of MeCP2
o 7d after SNI, and then downregulated. E, Relative protein level of
ut SNI. Error bars are SEM. *p < 0.05 (t test).
Figure 3 The role of MeCP2 in pain suppression. In WT mice,
hindpaws after SNI showed significant reduction in withdrawal
threshold compared to contralateral hindpaws in mechanical
von Frey test. But MeCP2 overexpression mice only had a slight
downgrade in paw withdrawal threshold and their withdrawal
threshold after SNI shows no diffierence compared with WT
contralateral. 9 mice were tested in each group. All values are
represented as means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 4 Change of MeCP2 transcript, miR-132 and p-CREB after SNI. A, M
downregulated by 3d to 7d after SNI. RNAs were collected from lumbar sp
miR-132 were analyzed by qPCR. C, p-CREB(Ser133) was elevated by 3 days
expression in spinal cord. Bars are relative protein level to control without
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Mechanisms of acute and chronic pain and common
treatments
Acute pain is defense mechanism that protects body
from noxious harmful stimuli, which is essential to an
organism’s survival and wellbeing. When physical dam-
age occurs or short-term pain is not properly treated,
acute pain can develop into chronic pain, a kind of dis-
ease that can evoke persistent pain without any noxious
stimuli or enhanced sensitization to noxious stimuli,
which is termed as allodynia and hyperalgesia in clinics.
Chronic pain happens due to increased spontaneous fir-
ing or alterations in neurotransmitter properties at per-
ipheral level or alterations in excitatory neurotransmitter
secretion, inhibitory interneurons and glial-neuronal in-
teractions at central level. Common treatments are cen-
tered around non-steroidal anti-inflammatory drugs
(NSAIDs) and opiates and are susceptible to addiction
and respiratory depression. New therapeutic strategies
with efficiency and less side effects are still highly
demanded. Since ReTT syndrome patients with MeCP2eCP2 transcript did not change significantly after SNI. B, miR-132 was
inal cord L4-L6 lysates of WT mice. Levels of MeCP2 transcript and
after SNI and then fell off. D, Relative protein level of p-CREB
SNI. Error bars are SEM. *p < 0.05 , **p < 0.01 (t test).
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targeting MeCP2 in local region, which is responsible for
pain sensation but not other physiological functions will
take more attention in future study.
Pain and memory share similar mechanisms
Synaptic plasticity is fundamental to many neurobio-
logical functions, including learning and memory as well
as pain. Synaptic strength is dynamic rather than static
in response to changes in transmitter release from pre-
synaptic terminals or response of the postsynaptic mem-
brane. MeCP2 is found in regulating synaptic characters
through its targets which responsible for synaptic plasti-
city [29]. Both deficiency and dulplication of MeCP2 can
change density of the dendrits and morphology of den-
dritic spines. By studying brain areas such as hippocampus
do people identified the electrophysiological properties of
LTP (long-term potentiation) and morphological change
of dendritic spines. LTP (long-term potentiation) and LTD
(long-term depression) are highly associated with forma-
tion of learning and memory and are based on synaptic
plasticity. Same mechanism is seen in pain transmission,
comprising an activity-dependent, long-lasting facilitation
of synaptic excitatory postsynaptic potentials in response
to brief, high-frequency repeated trains of nociceptor in-
put. This can be deemed as central sensitization under
chronic pain. Researchers could pay close attention to the
mechanisms of MeCP2 responsible for synaptic plasticity
in the induction and maintenance of central sensitization
for analgesic therapy.
MicroRNAs in pain signalling pathway
MicroRNAs are small, noncoding RNA molecules that
direct the post-transcriptional suppression of gene expres-
sion. They have antisense complementarity to multiple
sites in the 3′UTR of target genes, raising RNA-induced
silencing complex (RISC) to cleave the mRNAs or prevent
mRNAs from translation. MicroRNAs are involved in sev-
eral developmental, physiological, and pathophysiological
processes and play an important role in neurogenesis,
neuron survival, dendritic outgrowth, and spine formation.
Few studies have addressed the role of miRNAs in neuro-
pathic pain. Some miRNAs link to pain-related patho-
physiology while some miRNAs alleviate neuropathic pain
in spinal cord. The microRNA212/132 family is one of the
most studied miRNA family closely related to MeCP2.
Transgenic miR-132 alters neuronal spine density and im-
pairs novel object recognition memory. Klein et al. have
proposed a homeostatic feedback mechanism that as a tar-
get of MeCP2, BDNF induces miR-132 synthesis through
CREB pathway, miR-132 in turn silence MeCP2 expres-
sion [21]. Thereby, the neuroprotective response of
MeCP2 induced by getting rid of miR-132 inhibition is
speculated and demonstrated.Study limitations and perspective
Genetic background affects nociceptive pain sensitivity
in animals and may influence susceptibility to the devel-
opment of persistent pain. MeCP2 transgenic mice used
in experiments are systemically overexpressed in whole
body. Thus its distinction in behavioral phenotypes from
WT may not be confined to spinal cord. A local overex-
pression and knockdown of MeCP2 in spinal cord is yet
to be produced for further study of the analgesia of
MeCP2 at central level.
Conclusions
MeCP2 alleviated acute pain and neuropathic pain
through P-CREB/miR-132 pathway in spinal cord.
Methods
Animals
FVB mice were purchased from Nanjing Biomedical
Research Institute of Nanjing University. mecp2 TG
mice (008679) were purchased from Jackson Laboratory.
Animals were kept in their home cage at 21°C and 55%
relative humidity with a 12 h light/dark cycle and were
fed food and water adlibitum. All animal experiments
were approved by the Animal Experiments Committee
(Approval No. DWSY0121) of the Institute of Life
Sciences at Southeast University in accordance with the
International Association for Study of Pain regulation.
Surgeries
The spared nerve injury (SNI) model was used in experi-
ments. Animals were anaesthetized with 10% chloral hy-
drate under intraperitoneal injection. Skin of left knees
were opened and the muscle layer were separated to expose
the sciatic nerve. 5-0 suture is applied around the tibial and
common peroneal nerves, while the sural nerve is left to be
completely intact. Then a tight surgical knot is made and a
short section below the knot is cut. Next the muscle layer
is gently closed and sutured. The right knees were also sub-
mitted to exposure the sciatic nerve without injury as con-
trol. Animals were recovered 2 days before behavior test.
Behavior tests
von Frey test Mice were placed in blue colored plastic
cylinders placed on a wire mesh table. Habituated for 1
hour in cylinders prior to testing. Applied von Frey fila-
ments to the lateral part of the paw. Response in four
out of eight stimuli is regarded as a positive reaction.
Tail immersion The animals’ tails were placed in a
water bath heated to 48°C and 52°C respectively, and the
latency of response was measured upon tail flicking. The
cut-off time of 20 s was set to prevent tail skin tissue
damage. Each animal was tested for 3 times, and interval
at least 10 min.
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Mice were deeply anaesthetized with 10% chloral hy-
drate. Perfusion was performed with PBS followed by 4%
paraformaldehyde (PFA) in 0.1 M phosphate buffer pre-
fixation. DRG or lumbar spinal cord L4-L6 were dis-
sected for a post- fixation into 4% PFA for one day then
transferred to 30% sucrose solutions for 3 days. Tissues
were embedding by OCT at -20°C. Frozen sections were
made in 10 μm(DRG) and 25 μm (spinal cord). Sections
were washed in PBS, blocked with 10% donkey serum,
permeabilized in PBS containing 0.3% Triton X-100
(PBT) for 2 h, and incubated with anti-MeCP2 antibody
(CST, #3456, 1:500), anti-NF200 antibody(SIGMA, N0142,
1:250), anti-TRPV1 antibody(Millipore, MAB5568, 1:600)
diluted in blocking solution at least 16h at 4°C. Sections
were subsequently washed in PBS, incubated with the
anti-rabbit IgG-FITC (Santa Cruz, sc-2090, 1:300), anti-
mouse IgG-CFL 647 (Santa Cruz, sc-362288, 1:300) and
Isolectin GS-IB4 (Invitrogen, 121412, 1:1000) for 2 h at
room temperature and washed with PBS three times. As a
last step, coverslips were applied.
Quantitative real-time PCR assays
Total RNA was extracted from mice L4-L6 spinal cord
using mirVana miRNA Isolation Kit (Ambion). For the
measurement of primary miRNA transcripts, the large-
sized RNA fractions (>200 bp) were used for reverse
transcription. cDNA was synthesized by poly-dT primers
from 1 mg of purified RNA (>200 bp fraction) by iScript
cDNA Synthesis Kit (Bio-Rad). SYBR Premix Ex Taq
from Takara was used in this study. Quantitative real-
time PCR was performed with the Rotor-Gene Q ma-
chine (QIAGEN). Results were normalized to GAPDH,
and data analysis was done by using the comparative CT
method in software by QIAGEN.







For western blot analysis, total proteins were extracted
from mice L4-L6 DRG and spinal cord using FDTMRIPA
Buffer add protease inhibitors and phosphatase inhibitors
(Roche). Protein sample was separated on a 10% polyacryl-
amide gel and electrotransferred to nitrocellulose mem-
brane (Milipore). Membranes were blocked in 5% skim
milk at room temperature for 1h and then incubated with
primary antibody at 4°C overnight. After washing with
TBST, membranes were incubated with HRP-conjugated
secondary antibody at room temperature for 1h. Targeted
proteins were visualized with the SuperSignal(R) WestPico Chemiluminescent Substrate (Thermo Scientific).
Primary antibody were used as follows: anti-MeCP2
antibody (CST, #3456, 1:1000). anti-Tubulin antibody
(CST, #2125, 1:1000). anti-CREB antibody (CST, #9197,
1:1000). anti-p-CREB antibody (Santa Cruz, sc7978,
1:200). Secondary antibody were used as follows: Goat
anti-rabbit IgG-HRP (ABmart). Donkey anti-goat IgG –
HRP (ABclonal).
Statistical analysis
All the data were analyzed with Student’s t test, and P
values of less than 0.05 were regarded as statistically sig-
nificant (indicated with an asterisk in summary graphs).
Values were presented as means ± standard errors of the
means (SEM).
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